Recombinant yarrowia lipolytica with high yield of 2 '-fucosyllactose as well as construction method and application of recombinant yarrowia lipolytica

By constructing a multigene integration vector in Yarrowia lipolytica and knocking out the Pfk gene, the genetic stability and low yield of recombinant bacteria was solved, and efficient production of 2′-fucosyl lactose was achieved to meet industrial needs. .

CN118956632APending Publication Date: 2024-11-15JIANGNAN UNIV +1
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202411203896.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing recombinant Yarrowia lipolytica has poor genetic stability in exogenous genes, resulting in low yield and low production efficiency of 2′-fucosyl lactose, which cannot meet the needs of industrial applications.

Method used

By constructing the original pUU plasmid vector and the original pLU plasmid vector, the tandem polygenic integration was integrated into the Ura3 or Leu site on the Yarrowia lipolytic genome, integrating the expression of the lactose transporter Lac12 and strengthening GDP-mannose-4,6-dehydrase Gmd, GDP-L-fucose synthase Gmer and fucosyltransferase SUMO-FutC genes, and knock out the 6-phosphate fructose kinase Pfk gene to improve the genetic stability and yield of the gene.

Benefits of technology

The yield and production efficiency of 2′-fucosyl lactose was significantly improved, reaching a titer of 102.82g/L and a production efficiency of 0.86g/L/h, meeting industrial production needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956632A_ABST
    Figure CN118956632A_ABST
Patent Text Reader

Abstract

The invention discloses recombinant yarrowia lipolytica with high yield of 2 '-fucosyllactose as well as a construction method and application of the recombinant yarrowia lipolytica. According to the recombinant yarrowia lipolytica, a lactose transporter Lac12 gene, an enhanced GDP-mannose-4, 6-dehydratase Gmd gene, an enhanced GDP-L-fucose synthase Gmer gene and an enhanced fucosyltransferase SUMO-FutC gene added with an SUMO tag are integrally expressed on a chromosome, and meanwhile, a 6-phosphofructokinase Pfk gene on the chromosome is knocked out, so that the recombinant yarrowia lipolytica is obtained. The yield of the 2 '-fucosyllactose is increased to 102.82 g / L, the production efficiency is 0.86 g / L / h, and the 2'-fucosyllactose has the capacity of high yield of the 2 '-fucosyllactose.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of bioengineering, and in particular to a recombinant Yarrowia lipolytica capable of producing high 2'-fucosyllactose, a construction method and application thereof. Background Art

[0002] 2′-fucosyllactose (C 18 H 32 O 15 ) is an oligosaccharide formed by the condensation of lactose and fucose. It is the most abundant human milk oligosaccharide. Studies have shown that 2′-fucosyllactose has the effect of resisting viral and bacterial infections. It can also be used as a prebiotic to promote the establishment of a healthy intestinal microbial environment in the body, thereby improving the infant's digestive system, and has the effect of reducing the risk of pathogen infection and regulating immune response. Studies have reported that adding 2′-fucosyllactose to infant formula powder can produce similar beneficial effects on infants as 2′-fucosyllactose in breast milk. At present, 2′-fucosyllactose is mainly used in milk powder and functional foods as a functional food ingredient.

[0003] At present, there are four main methods for obtaining 2′-fucosyllactose. Compared with traditional methods (extracted from milk sources), chemical synthesis, and chemical enzyme synthesis, the microbial method has the advantages of mild synthesis conditions, environmental friendliness, and high efficiency, and has received more and more research attention and application. At present, the main chassis strain for synthesizing 2′-fucosyllactose by microbial method is Escherichia coli. For example, Chinese invention patents CN202210571832.3, CN202010450707.8, and CN202010084247.1 all disclose methods for producing 2′-fucosyllactose using Escherichia coli as a chassis strain. However, Escherichia coli has not been listed as a GRAS food safety strain. In the production of nutritional supplement 2′-fucosyllactose, there are certain hidden dangers in its safety. For example, antibiotics are often needed during the fermentation process, endotoxins are produced, and there is a risk of being easily contaminated by bacteriophages, which has a great negative impact on safety and the stability of industrial production. In addition, when E. coli produces 2′-fucosyllactose, the precursor substances (lactose and GDP-fucose) for synthesizing 2′-fucosyllactose will be utilized by the metabolic pathway of E. coli itself, resulting in a low production conversion rate.

[0004] As a GRAS food safety strain, Yarrowia lipolytica has better safety in producing food supplement 2′-fucosyllactose. No antibiotics are required during the fermentation process and no endotoxins are produced. Secondly, Yarrowia lipolytica is tolerant to a variety of extreme environments and is suitable for the actual situation of industrial production. Moreover, in terms of synthesizing 2′-fucosyllactose, Yarrowia lipolytica does not have a metabolic pathway for degrading its precursors lactose and GDP-fucose, so a higher production conversion rate can be achieved. In terms of synthesizing 2′-fucosyllactose, Hollands et al. installed four exogenous gene expression cassettes in the metabolic pathway of synthesizing 2′-fucosyllactose in Yarrowia lipolytica on a free plasmid vector, expressed in a free manner, and by increasing the number of copies of the free vector, they finally obtained 2′-fucosyllactose with a titer of 24g / L after 55h of fermentation, with a production efficiency of 0.71g / L / h. (For details, see the reference: Hollands, Kerry, et al. "Engineering two species of yeast ascell factories for 2′-fucosyllactose." Metabolic Engineering 52 (2019): 232-242. For details, see patent: US11913046B2). In addition, Zhang et al. increased the number of exogenous gene copies in the 2′-fucosyllactose synthesis pathway, enhanced the supply of the precursor GDP-mannose, and enhanced the NADPH regeneration pathway to increase the yield of 2′-fucosyllactose. Finally, through 144 hours of fed-batch fermentation, 41.10 g / L of 2′-fucosyllactose was obtained, with a production efficiency of 0.31 g / L / h. (For details, see the reference: Zhang Y, Zhang X, Liu H, Hou J, Liu M, Qi Q. Efficient production of 2′-fucosyllactose in unconventional yeast Yarrowia lipolytica. Synthetic and Systems Biotechnology. 2023 Dec 1; 8(4): 716-23.). However, in the prior art, there are problems such as poor genetic stability of exogenous genes in recombinant Yarrowia lipolytica, easy loss of exogenous genes when there are multiple copies, inability to efficiently produce 2′-fucosyllactose by long-term fermentation, low yield of 2′-fucosyllactose synthesized by recombinant Yarrowia lipolytica strains, and low production efficiency, which cannot meet potential industrial applications and production. Summary of the invention

[0005] In view of the deficiencies of the prior art, the present invention provides a recombinant Yarrowia lipolytica with high 2′-fucosyllactose production, and a construction method and application thereof. The present invention constructs an original pUU plasmid vector and an original pLU plasmid vector, and integrates multiple genes in series into the Ura3 or Leu site on the Yarrowia lipolytica genome. The construction method is simple and efficient, and the constructed recombinant Yarrowia lipolytica can maintain the genetic stability of the target gene, and the yield and production efficiency of 2′-fucosyllactose are significantly improved, which can meet the needs of industrial production.

[0006] The technical solution of the present invention is as follows:

[0007] A recombinant Yarrowia lipolytica with high production of 2′-fucosyllactose, wherein the recombinant Yarrowia lipolytica has integrated expression of a lactose transporter Lac12 gene, an enhanced GDP-mannose-4,6-dehydratase Gmd gene, an enhanced GDP-L-fucose synthase Gmer gene, and an enhanced SUMO-tagged fucosyltransferase SUMO-FutC gene on its chromosome, and the 6-phosphofructokinase Pfk gene on the chromosome is knocked out.

[0008] Furthermore, the recombinant Yarrowia lipolytica uses Yarrowia lipolytica Po1f as a host.

[0009] Furthermore, the nucleotide sequence of the Lac12 gene is shown in SEQ ID NO.3; the nucleotide sequence of the Gmd gene is shown in SEQ ID NO.4; the nucleotide sequence of the Gmer gene is shown in SEQ ID NO.5; the nucleotide sequence of the SUMO-FutC gene and the Lac12 gene is shown in SEQ ID NO.6; the NCBI gene number of the 6-phosphofructokinase Pfk gene is YALI2_D00323g; the promoters of the Gmd gene, Gmer gene, and SUMO-FutC gene are the Yarrowia lipolytica promoter P TEF , the terminator is the Yarrowia lipolytica terminator T LIP .

[0010] Furthermore, the copy number of the lactose transporter Lac12 gene is 1, the copy number of the enhanced GDP-mannose-4,6-dehydratase Gmd gene is 2, the copy number of the enhanced GDP-L-fucose synthase Gmer gene is 2, and the copy number of the enhanced SUMO-tagged fucosyltransferase SUMO-FutC gene is 2; the enhancing element used to enhance the Gmd gene and the Gmer gene is 4UAS; the enhancing element used to enhance the SUMO-FutC gene is 4UAS and / or 8UAS.

[0011] Furthermore, the recombinant Yarrowia lipolytica uses the original pUU plasmid vector and / or the original pLU plasmid vector as an integration expression vector; the sequence of the original pUU plasmid vector is shown in SEQ ID NO.1; the original pLU plasmid vector is shown in SEQ ID NO.2.

[0012] A method for constructing the recombinant Yarrowia lipolytica comprises the following steps:

[0013] (1) Insert the target gene Lac12 gene, Gmd gene, Gmer gene, and SUMO-FutC gene into the BamH I and Hind III sites of the original PUU plasmid vector, respectively, to obtain pUU-Lac12 plasmid, pUU-Gmd plasmid, pUU-Gmer plasmid, and pUU-FutC plasmid;

[0014] (2) PCR amplification was performed using pUU-Lac12 plasmid, pUU-Gmd plasmid, and pUU-Gmer plasmid as templates to obtain P TEF -Lac12-T LIP Expression cassette, 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP expression cassette; pUU-FutC plasmid was digested with restriction endonuclease EcoR I to obtain linearized pUU-FutC plasmid, and then 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP Expression cassette, P TEF -Lac12-T LIP The expression cassette was ligated with the linearized pUU-FutC plasmid vector to obtain the pUU-FGGL recombinant plasmid;

[0015] (3) PCR amplification was performed using the pUU-FutC plasmid as a template to obtain the SUMO-FutC fragment, and the original pLU plasmid vector was digested with restriction endonucleases BamH I and Hind III to obtain a linearized pLU plasmid vector. The SUMO-FutC fragment was then connected to the linearized pLU plasmid vector using the homologous recombinase C115 to obtain the pLU-FutC recombinant plasmid. Then, PCR amplification was performed using the pUU-Gmd plasmid and the pUU-Gmer plasmid as templates to obtain the 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-TLIP expression cassette; the pLU-FutC recombinant plasmid was digested with restriction endonuclease Sal I to obtain a linearized pLU-FutC recombinant plasmid vector, and then the 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP The expression cassette was connected to the linearized pLU-FutC recombinant plasmid vector to obtain the pLU-FGG recombinant plasmid;

[0016] (4) using restriction endonuclease Not I to digest the pUU-FGGL recombinant plasmid to obtain a linearized pUU-FGGL recombinant plasmid, transforming it into competent cells of Yarrowia lipolytica Polf for homologous recombination, and then introducing the pYLXP-Cre plasmid to eliminate the Ura selection marker after screening and PCR identification, and then obtaining positive clones successfully introduced with the pYLXP-Cre plasmid after screening and PCR identification, and then continuously passaged to lose the pYLXP-Cre plasmid to obtain recombinant bacteria 1;

[0017] (5) The recombinant plasmids pg7-Leu and pCg58-Ura3 were transformed into recombinant bacteria 1, and the pfk gene was knocked out by CRISPR-Cas9 technology. The colonies with successful knockout of the pfk gene were obtained by screening and colony PCR identification, and the recombinant plasmids pg7-Leu and pCg58-Ura3 were lost by subculture to obtain recombinant bacteria 2;

[0018] (6) The pLU-FGG recombinant plasmid was recombined using restriction endonuclease Not I to obtain a linearized pLU-FGG recombinant plasmid, which was transformed into competent cells of the recombinant bacteria 2 for integration. After screening and PCR identification, a recombinant Yarrowia lipolytica strain with high 2′-fucosyllactose production that was correctly identified by PCR was obtained.

[0019] A use of the recombinant Yarrowia lipolytica described in claim 1 or the recombinant Yarrowia lipolytica constructed by the construction method in producing 2′-fucosyllactose.

[0020] Furthermore, the recombinant Yarrowia lipolytica is activated and then inoculated into a fermentation medium for fed-batch fermentation to obtain 2′-fucosyllactose.

[0021] Furthermore, the fermentation medium is 2×YPG liquid medium, and the initial OD of the recombinant Yarrowia lipolytica in the fermentation medium is 600The value is 0.5-1.0, the temperature of the fed-batch fermentation is 28-30°C, the rotation speed is 200-1200rpm, the dissolved oxygen content is 15-25%, the ventilation volume is 3v / v / min, and the pH is 6.0; the fed-batch fermentation is specifically as follows: when the fermentation is 12h, 10g / L lactose is added to the culture medium to prepare 2′-fucosyllactose, and when the initial glycerol in the culture medium is consumed, 3.5-4.5g / L / h glycerol, 1.5-2.0g / L / h glucose and 0.5-1.3g / L / h lactose are added by flow, and the total fermentation time is 132h.

[0022] Furthermore, the titer of the 2′-fucosyllactose is 102.82 g / L, and the production efficiency is 0.86 g / L / h.

[0023] The beneficial technical effects of the present invention are:

[0024] The original pUU plasmid vector and the original pLU plasmid vector constructed by the present invention can integrate multiple genes in series into the Ura3 or Leu site on the Yarrowia lipolytica genome. The construction method is simple and efficient, and the recombinant Yarrowia lipolytica can maintain the genetic stability of the introduced genes.

[0025] The present invention uses the Yarrowia lipolytica enhanced promoter 4UAS-P TEF or 8UAS-P TEF The three key genes of GDP-mannose-4,6-dehydratase (Gmd), GDP-L-fucose synthase (Gmer) and fucosyltransferase (SUMO-FutC) on the 2′-fucosyllactose synthesis pathway were strengthened, and the 6-phosphofructokinase gene Pfk was knocked out to regulate the ability of recombinant Yarrowia lipolytica to utilize the mixed carbon source of glycerol and glucose, so that more carbon sources flowed to the product synthesis pathway. Finally, the recombinant Yarrowia lipolytica was able to stably and efficiently synthesize 2′-fucosyllactose. After 132 hours of fermentation, the titer of 2′-fucosyllactose was 102.82 g / L, and the production efficiency was 0.86 g / L / h. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 Metabolic diagram of the 2′-fucosyllactose synthesis pathway in Yarrowia lipolytica.

[0027] Figure 2 is the map of the original pUU plasmid vector.

[0028] Figure 3 This is the map of the pUU-FGGL recombinant plasmid.

[0029] Figure 4 Figure 2 is a map of the original PLU plasmid vector.

[0030] Figure 5 This is the map of the PLU-FGG recombinant plasmid.

[0031] Figure 6 Figure 2 is a map of the pYLXP-Cre plasmid.

[0032] Figure 7 This is the map of the pg7-Leu recombinant plasmid.

[0033] Figure 8 This is the map of the pCg58-Ura3 recombinant plasmid.

[0034] Fig. 9 This is an LC-MS detection diagram of 2′-fucosyllactose produced by the recombinant Yarrowia lipolytica in Example 4 of the present invention and a standard sample diagram of 2′-fucosyllactose.

[0035] Fig.10 This is a graph showing the production of 2′-fucosyllactose by the recombinant Yarrowia lipolytica in Example 4 of the present invention.

[0036] Fig.11 This is a graph showing the production of 2′-fucosyllactose by the recombinant Yarrowia lipolytica in Comparative Example 1 of the present invention.

[0037] Fig.12 This is a graph showing the production of 2′-fucosyllactose by the recombinant Yarrowia lipolytica in Comparative Example 2 of the present invention.

[0038] Fig.13 This is a graph showing the production of 2′-fucosyllactose by shake flask fermentation of the recombinant Yarrowia lipolytica YR02, YR03, YR04, and YR07 of the present invention. DETAILED DESCRIPTION

[0039] The present invention is described in detail below in conjunction with the accompanying drawings and embodiments.

[0040] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods.

[0041] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0042] In the present invention, the expression cassette is represented by: enhancing element-promoter-target gene-terminator or promoter-target gene-terminator.

[0043] The starting strain of Yarrowia lipolytica in the following examples is the Po1f strain, which can be purchased from the American Type Culture Collection and is numbered ATCC MYA-2613.

[0044] In the following examples, the pYLXP-Cre plasmid, pg7-Leu plasmid, and pCg58-Ura3 plasmid are all commercial recombinant plasmid vectors and can be obtained through commercial channels, such as from Addgene.

[0045] The nucleotide sequence of the original pUU plasmid vector constructed in the present invention is shown as SEQ ID NO.1, and the nucleotide sequence of the original pLU plasmid vector is shown as SEQ ID NO.2; the gene sequence of the target gene lactose transporter Lac12 in the present invention is shown as SEQ ID NO.3, the gene sequence of GDP-mannose-4,6-dehydratase Gmd is shown as SEQ ID NO.4, the gene sequence of GDP-L-fucose synthase Gmer is shown as SEQ ID NO.5, and the gene sequence of fucosyltransferase SUMO-FutC with SUMO tag added is shown as SEQ ID NO.6.

[0046] SEQ ID NO.1:

[0047]

[0048] SEQ ID NO.2:

[0049]

[0050] SEQ ID NO.3:

[0051]

[0052] SEQ ID NO.4:

[0053]

[0054] SEQ ID NO.5:

[0055] ATGTCTCCCTCTAAGTCTGTGATCATGGTGACCGGCGGCTCTGGCCTGGTGGGCAAGGCCATCGACTGGGTGGTGGAGAACGACTCTAAGTACGGCAAGCGAGAGGGCGAGGAGTGGGTGTTCCTGACCTCTAAGGACGGCAACCTGATCGACCCCGCTCAGACCAAGGCCATCTTCGAGAAGTACCGACCCACCCACGTGATCCACCTGGCCGCCAAGGTGGGCGGCCTGTTCGGCAACATGGCCGCCAACCTGGACTACTTCCGAGACAACCTGCTGATCAACGACAACGTGCTGCACAACGCCAAGGAGTTCGGCGTGAAGAAGGTGGTGTCTTGTCTGTCTACCTGTATCTTCCCCGACAAGACCTCTTACCCCATCGACGAGACCATGGTGCACCAAGGCCCCCCCCACGACTCTAACTACGGCTACTCTCACTCTAAGCGAATGGTGGACGTGATGAACCGAGCCTACAATCAGCAGTACGGCTGTAACTTCACCTCTGTGATCCCCACCAACGTGTTCGGCCCCCACGACAACTTCCACCTGGTGAACTCTCACGTGATCCCCGGCCTGATCCACAAGTGTTACCTGGCTCAGCAGAACAACACCCCCTTCATCATGGCCGGCACCGGCCGACCCCTGCGACAGTTCATCTACTCTCGAGACCTGGCCCGACTGTTCATCTGGACCCTGCGAGAGTACCAAGAGATCACCCCCCTGATCCTGTCTGTGCCCGAGGAAGAAGAGGTGTCTATCAAGCAAGTGGGCGACTCTATCGTGAAGGCCATGGGCTACACCGGCGACTACCGATTCGACACCACCAAGGCCGACGGACAGTACAAGAAGACCGCCTCTAACAAGAAGCTGATGTCTCTGAACCCCGACTTTCAGTTCACCCCCTTCGACGTGGCCCTGTCTGAGACCGTGGAGTGGTTCAAGGAGAACGTGGACACCATCCGAAAGTAA

[0056] SEQ ID NO.6:

[0057]

[0058] The primers used in the present invention are shown in Table 1.

[0059] Table 1

[0060]

[0061]

[0062] The NCBI gene number of the 6-phosphofructokinase Pfk gene in the present invention is YALI2_D00323g; the sgRNA-1 sequence used to knock out the Pfk gene is: CCTGGGCTTCCTCCCCACCA, and the sgRNA-2 sequence is: GAGGTCTACGCTGTCCGAGA.

[0063] The formula of the SD-Ura screening medium used in the present invention is: 20 g / L glycerol, 6.7 g / L YNB (amino-free yeast nitrogen source, purchased from BBI Life Sciences), 2 g / L Casamino acid (casein amino acids, purchased from BBI LifeSciences), and 18 g / L agar powder.

[0064] The formula of the SD-Leu screening medium containing 5-fluoroorotic acid used in the present invention is: 20 g / L glycerol, 6.7 g / L YNB, 100 mg / L Uracil (purchasing from BBI Life Sciences), 1 mg / L 5-fluoroorotic acid (purchasing from BBI Life Sciences), and 18 g / L agar powder.

[0065] The formula of the SD-Leu screening medium used in the present invention is: 20 g / L glycerol, 6.7 g / L YNB, 100 mg / L Uracil (purchasing from BBI Life Sciences), and 18 g / L agar powder.

[0066] The formula of the SD-Ura-Leu screening medium used in the present invention is: 20 g / L glycerol, 6.7 g / L YNB (amino-free yeast nitrogen source, purchased from BBI Life Sciences), and 18 g / L agar powder.

[0067] The YPG liquid culture medium used in the present invention is formulated as 1% yeast extract, 2% tryptone, and 20 g / L glycerol. If a solid culture medium is prepared, 2% agar powder is added. The 2×YPG liquid culture medium is formulated as: 2% yeast extract, 4% tryptone, and 40 g / L glycerol.

[0068] In the present invention, during the construction of plasmids, the homologous recombination enzyme ClonExpress Ultra OneStep Cloning Kit (C115) and the competent E. coli XL-10 were purchased from Nanjing Novozyme Biotechnology Co., Ltd., and the restriction endonucleases were purchased from Bio-Rad Biotechnology (Beijing) Co., Ltd. The primer synthesis and sequencing business were entrusted to Suzhou Jinweizhi Biotechnology Co., Ltd.

[0069] Figure 1 The metabolic diagram of the 2′-fucosyllactose synthesis pathway in Yarrowia lipolytica of the present invention, wherein Lac12 is a lactose transporter; Gmd is a GDP-mannose-4,6-dehydratase; Gmer is a GDP-L-fucose synthase; FutC is a fucosyltransferase, and Pfk is a knocked-out 6-phosphofructokinase gene. GDP-L-fucose is generated intracellularly by GDP-mannose-4,6-dehydratase and GDP-L-fucose synthase, and then lactose and GDP-L-fucose are combined by fucosyltransferase to generate 2′-fucosyllactose.

[0070] Example 1 Preparation of original plasmid vector and acquisition of target gene

[0071] (1) Preparation of original plasmid vector

[0072] Original pUU plasmid vector: Figure 2 This is a schematic diagram of the original pUU plasmid vector, which was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd. according to the nucleotide sequence SEQ ID NO.1 of the original pUU plasmid vector. Among them, URA-UP on the original pUU plasmid vector is a sequence of 1017 bp upstream of the URA gene in the Yarrowia lipolytica genome (upstream homology arm), URA-DOWN is a sequence of 888 bp downstream of the URA gene in the Yarrowia lipolytica genome (downstream homology arm), and 4UAS is a TEF promoter enhancing element.

[0073] Original pLU plasmid vector: Figure 4 This is a schematic diagram of the original pLU plasmid vector, which was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd. according to the nucleotide sequence SEQ ID NO.2 of the original pLU plasmid vector. Among them, Leu-UP on the original pLU plasmid vector is a sequence of 1110 bp upstream of the Leu gene in the Yarrowia lipolytica genome (upstream homology arm), Leu-DOWN is a sequence of 948 bp downstream of the Leu gene in the Yarrowia lipolytica genome (downstream homology arm), and 8UAS is a TEF promoter enhancing element.

[0074] (2) Acquisition of target genes

[0075] pUU-Lac12 plasmid: According to the lactose transporter Lac12 sequence from Kluyveromyces lactis provided by NCBI (NCBI sequence number: KLLA0_B14861g), after codon optimization, it was commissioned to Suzhou Jinweizhi Biotechnology Co., Ltd. to synthesize according to the Lac12 gene sequence SEQ ID NO.3, and inserted between the BamH I and Hind III sites on the original pUU plasmid vector obtained in Example 1 to obtain the pUU-Lac12 plasmid.

[0076] pUU-Gmd plasmid: According to the GDP-mannose-4,6-dehydratase Gmd sequence from Mortierella alpina (Mortierella.alpina) provided on NCBI (NCBI sequence number: ADC54120), after codon optimization, Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to synthesize it according to the Gmd gene sequence SEQ ID NO.4, and inserted between the BamH I and Hind III sites on the original pUU plasmid vector obtained in Example 1 to obtain the pUU-Gmd plasmid.

[0077] pUU-Gmer plasmid: According to the GDP-L-fucose synthase Gmer sequence from Mortierella alpina (Mortierella.alpina) provided by NCBI (NCBI sequence number: ADC54121), after codon optimization, Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to synthesize it according to the Gmer gene sequence SEQID NO.5, and inserted between the BamH I and Hind III sites on the original pUU plasmid vector obtained in Example 1 to obtain the pUU-Gmer plasmid.

[0078] pUU-FutC plasmid: According to the fucosyltransferase FutC sequence from Helicobacter pylori provided by NCBI (NCBI sequence number: WP_026938579), after codon optimization, a SUMO tag was added to the N-terminus of the enzyme, and Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to synthesize the optimized fucosyltransferase encoding gene SUMO-FutC according to the SUMO-FutC gene sequence SEQ ID NO.6, and inserted between the BamH I and Hind III sites on the original pUU plasmid vector obtained in Example 1 to obtain the pUU-FutC plasmid.

[0079] Example 2 Construction of recombinant plasmid

[0080] (1) Construction of pUU-FGGL recombinant plasmid

[0081] Figure 3This is a schematic diagram of the pUU-FGGL recombinant plasmid. The construction method is as follows:

[0082] a. Using pUU-Gmd plasmid as template, PCR amplification was performed using primers 1-F and 1-R to obtain 4UAS-P TEF -Gmd-T LIP expression cassette;

[0083] b. Using pUU-Gmer plasmid as template, PCR amplification was performed using primers 2-F and 2-R to obtain 4UAS-P TEF -Gmer-T LIP expression cassette;

[0084] c. Using pUU-Lac12 plasmid as template, PCR amplification was performed using primers 3-F and 3-R to obtain P TEF -Lac12-T LIP expression cassette;

[0085] d. digesting the pUU-FutC plasmid with restriction endonuclease EcoR I to obtain a linearized pUU-FutC plasmid vector;

[0086] e. 4UAS-P was transformed into 4UAS-P by homologous recombinase C115. TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP Expression cassette, P TEF -Lac12-T LIP The expression cassette was connected to the linearized pUU-FutC plasmid vector to obtain the pUU-FGGL recombinant plasmid, and the obtained pUU-FGGL recombinant plasmid was introduced into Escherichia coli XL-10 competent cells for storage and amplification.

[0087] (2) Construction of pLU-FGG recombinant plasmid

[0088] Figure 5 This is a schematic diagram of the pLU-FGG recombinant plasmid. The construction method is as follows:

[0089] a. Using pUU-FutC plasmid as template, PCR amplification was performed using primers 4-F and 4-R to obtain SUMO-FutC fragment;

[0090] b. The original pLU plasmid vector was digested with restriction endonucleases BamH I and Hind III to obtain a linearized pLU plasmid vector, and the SUMO-FutC fragment was connected to the linearized pLU plasmid vector by homologous recombinase C115 to obtain a pLU-FutC recombinant plasmid, and the obtained pLU-FutC recombinant plasmid was introduced into Escherichia coli XL-10 competent cells for storage and amplification;

[0091] c. Using pUU-Gmd plasmid as template, PCR amplification was performed using primers 5-F and 1-R to obtain 4UAS-P TEF -Gmd-T LIP expression cassette;

[0092] d. Using pUU-Gmer plasmid as template, PCR amplification was performed using primers 2-F and 5-R to obtain 4UAS-P TEF -Gmer-T LIP expression cassette;

[0093] e. The pLU-FutC recombinant plasmid was digested with restriction endonuclease Sal I to obtain a linearized pLU-FutC recombinant plasmid vector, and then the 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP The expression cassette was connected to the linearized pLU-FutC recombinant plasmid vector to obtain the pLU-FGG recombinant plasmid, and the obtained pLU-FGG recombinant plasmid was introduced into Escherichia coli XL-10 competent cells for storage and amplification.

[0094] (3) Construction of pg7-Leu recombinant plasmid

[0095] Figure 7 Schematic diagram of pg7-Leu recombinant plasmid, the pg7-Leu recombinant plasmid is used to knock out the Pfk gene, and the construction method is as follows:

[0096] The commercially purchased pg7-Leu plasmid was used as a template, and primers Sg-1-F and Sg-1-R were used for PCR amplification (using the 20bp sgRNA-1 on the Sg-1-F and Sg-1-R primers as the homology arm). The amplified product fragments were homologously recombined using C115 to obtain the pg7-Leu recombinant plasmid for knocking out the Pfk gene. The obtained pg7-Leu recombinant plasmid was introduced into Escherichia coli XL-10 competent cells for storage and amplification.

[0097] (4) Construction of pCg58-Ura3 recombinant plasmid

[0098] Figure 8 Schematic diagram of pCg58-Ura3 recombinant plasmid, the pCg58-Ura3 recombinant plasmid is used to knock out the Pfk gene, the construction method

[0099] Using the initial vector pCg58-Ura as a template, primers Sg-2-F and Sg-2-R were used for PCR amplification (using the 20bp sgRNA-2 on the Sg-2-F and Sg-2-R primers as homology arms), the amplified product fragments were homologously recombined using C115, and the pCg58-Ura3 recombinant plasmid for knocking out the Pfk gene was obtained after the reaction. The obtained pCg58-Ura3 recombinant plasmid was introduced into E. coli XL-10 competent cells for preservation and amplification.

[0100] Example 3 The method for constructing a recombinant Yarrowia lipolytica with high 2′-fucosyllactose production is as follows:

[0101] (1) Construction of recombinant bacteria 1

[0102] ① Use Zymogen Frozen EZ Yeast Transformation Kit II from Zymo Research Corporation to prepare competent cells of Yarrowia lipolytica Polf; use restriction endonuclease Not I to digest the pUU-FGGL recombinant plasmid constructed in Example 2 to obtain a linearized pUU-FGGL recombinant plasmid, which is then transformed into competent cells of Yarrowia lipolytica Polf for homologous recombination. (For specific methods, see the instructions for the Zymogen Frozen EZ Yeast Transformation Kit II)

[0103] ② Then use SD-Ura screening medium to screen positive clones (bacteria that can grow on SD-Ura screening medium are positive clones), obtain positive clones, and perform PCR identification.

[0104] ③ After the positive clones identified by PCR in step ② were inoculated into YPG liquid culture medium for overnight culture, competent cells were prepared using the Zymogen Frozen EZ Yeast Transformation Kit II kit, and the pYLXP-Cre plasmid was transformed into the cells (the pYLXP-Cre plasmid carries a Leu selection marker).

[0105] ④ Use SD-Leu screening medium containing 5-fluoroorotic acid to screen positive clones that have lost the Ura screening marker (the bacteria successfully transformed with the pYLXP-Cre plasmid that can grow on the SD-Leu screening medium containing 5-fluoroorotic acid are positive clones), wherein the components of the screening medium are: 20 g / L glycerol, 6.7 g / L YNB, 100 mg / L Uracil (uracil, purchased from BBI Life Sciences), 1 mg / L 5-fluoroorotic acid (purchased from BBI Life Sciences), and 18 g / L agar powder.

[0106] ⑤ Gently scrape a small amount of the positive clone grown in step ④ with a sterile 10μl pipette tip, transfer it to a YPG solid culture medium plate containing 20g / L glycerol, and culture it at 30℃ until a single colony grows. Repeat the transfer step 3 times to eliminate the pYLXP-Cre plasmid, and then transfer it to the plates of SD-Leu screening medium and SD-Ura screening medium respectively, and culture it at 30℃ for 48-72h. Observe the growth of the bacteria, and select the single colony that cannot grow in both SD-Leu screening medium and SD-Ura screening medium as the positive clone, named recombinant bacteria 1.

[0107] (2) Construction of recombinant bacteria 2

[0108] ① Use Zymogen Frozen EZ Yeast Transformation Kit II from Zymo Research Corporation to prepare competent cells of recombinant bacteria 1, and transform the recombinant plasmids pg7-Leu and pCg58-Ura3 into competent cells of recombinant bacteria 1 to knock out the Pfk gene.

[0109] ② Use SD-Ura-Leu screening medium to screen positive clones (those that can grow in SD-Ura-Leu screening medium are bacteria that have successfully transferred the recombinant plasmids pg7-Leu and pCg58-Ura3, and are positive clones), wherein the screening medium SD-Ura-Leu contains: 20 g / L glycerol, 6.7 g / L YNB (amino-free yeast nitrogen source, purchased from BBI Life Sciences), and 18 g / L agar powder.

[0110] ③ The positive clones in step ② were identified by colony PCR, where the PCR primers were 6PF-YR-F and 6PF-YR-R. If the Pfk gene was not knocked out, the result of colony PCR was 1244 bp; if the Pfk gene was knocked out, the result of colony PCR was 662 bp.

[0111] ④ Select the single colony in which the Pfk gene was knocked out in step ③, gently scrape a small amount with a sterile 10μl pipette tip, transfer it to the YPG solid culture medium plate containing 20g / L glycerol, and culture it at 30℃ until a single colony grows out. Repeat the transfer step 3 times to discard the pg7-Leu and pCg58-Ura3 plasmids, and then transfer them to the solid screening culture medium SD-Leu and SD-Ura plates respectively, and culture them at 30℃ for 48-72h. Observe the growth of the bacteria, and select the single colony that cannot grow on both SD-Leu and SD-Ura plates as the positive clone and recombinant bacteria 2. The obtained recombinant bacteria are named YR02.

[0112] (3) Construction of recombinant bacteria 3

[0113] ① Use the Zymogen Frozen EZ Yeast Transformation Kit II kit to prepare the competent cells of recombinant bacteria 2, then cut the linearized pLU-FGG recombinant plasmid with endonuclease Not I and add it to the competent cells of recombinant bacteria 2 for homologous recombination.

[0114] ② Use SD-Ura screening medium to screen positive clones (bacteria that can grow on SD-Ura screening medium are positive clones) and perform PCR identification. The screening medium SD-Ura contains: glycerol 20g / L, YNB 6.7g / L, Casamino acid 2g / L, agar powder 18g / L.

[0115] ③ After PCR identification, the correct positive clone was recombinant strain 3, which was the final recombinant Yarrowia lipolytica strain with high 2′-fucosyllactose production. The obtained recombinant strain was named YR-07.

[0116] Example 4

[0117] The application of a recombinant Yarrowia lipolytica YR-07 engineered strain in the production of 2′-fucosyllactose is as follows:

[0118] (1) Fed-batch fermentation of engineered bacteria and production of 2′-fucosyllactose.

[0119] The YR-07 engineered strain was activated in solid YPG (carbon source: 20 g / L glycerol) medium for 24 h, and a single colony was picked to 10 mL SD-Ura liquid medium (carbon source: 20 g / L glycerol) for the second activation, and then transferred to 100 mL SD-Ura liquid medium (carbon source: 20 g / L glycerol) for the third activation, and finally transferred to a 5 L fermentor containing 2.5 L 2×YPG fermentation medium (2% yeast extract, 4% tryptone, 40 g / L glycerol) for fed-batch fermentation. The initial OD600 The pH value was 0.5 to 1.0. NaOH and H2SO4 were used to control the pH value to 6.0, and the DO was controlled at 20% by controlling the stirring speed to 200 to 1200 rpm, and the ventilation was maintained at 3v / v / min. At 12h of fermentation, lactose was added to the culture medium to a concentration of 10g / L to start the preparation of 2′-fucosyllactose. When the initial glycerol in the culture medium was consumed, 3.5 to 4.5g / L / h glycerol, 1.5 to 2.0g / L / h glucose and 0.5 to 1.3g / L / h lactose were added for feeding, and the total fermentation was 132h.

[0120] (2) Determination of carbon source and product in fermentation broth

[0121] The concentrations of 2′-fucosyllactose, glucose, glycerol and lactose were determined by HPLC, specifically:

[0122] Thermo UltiMate 3000 high performance liquid chromatography and Dikma CarboPac H+6μm chromatographic column were used; the column temperature was set to 50°C, the temperature of the differential refractive index detector was set to 35°C; 5mM H2SO4 was used as the mobile phase (0.8mL / min). Fermentation broth treatment method: 1mL of the fermentation broth prepared in this example was boiled for 10min to lyse the cells, and the supernatant was collected by centrifugation (12 000g, 20min) and detected by high performance liquid chromatography. The results are shown in Fig.10 As shown by Fig.10 The results showed that after 132 h of fermentation, the final titer of 2′-fucosyllactose was 102.82 g / L and the production efficiency was 0.86 g / L / h.

[0123] Comparative Example 1

[0124] The use of a recombinant Yarrowia lipolytica (recombinant bacteria 1 in Example 3) in the production of 2′-fucosyllactose is as follows:

[0125] (1) Production of 2′-fucosyllactose by shake flask fermentation

[0126] The recombinant bacteria 1 constructed in Example 3 was inoculated into a 250 mL shake flask containing 30 mL of culture medium and fermented on a shaker at 30°C and 220 rpm for 96 h. 600 The value is 0.6. The formula of the culture medium is: 1% yeast extract, 2% tryptone, 20g / L glycerol, 10g / L glucose, and 10g / L lactose.

[0127] (2) Determination of carbon source and product in fermentation broth

[0128] The concentrations of 2′-fucosyllactose, glucose, and glycerol were determined by high performance liquid chromatography, specifically:

[0129] Thermo UltiMate 3000 high performance liquid chromatography and Dikma CarboPac H+6μm chromatographic column were used; the column temperature was set to 50°C, the differential refractive index detector temperature was set to 35°C; 5mM H2SO4 was used as the mobile phase (0.8mL / min). Fermentation broth treatment method: 1mL of the fermentation broth prepared in this comparative example was boiled for 10min to lyse the cells, the supernatant was collected by centrifugation (12 000g, 20min) and detected by high performance liquid chromatography. The results are shown as follows: Fig.11 As shown by Fig.11 The results show that after 96 hours of fermentation of the recombinant bacteria 1 in Example 3, the final titer of 2′-fucosyllactose was 5.67 g / L.

[0130] Comparative Example 2

[0131] The application of a recombinant Yarrowia lipolytica (YR02 in Example 3) in the production of 2′-fucosyllactose is as follows:

[0132] (1) Production of 2′-fucosyllactose by shake flask fermentation

[0133] YR02 in Example 3 was inoculated into a 250 mL shake flask containing 30 mL of culture medium and fermented on a shaker at 30°C and 220 rpm for 96 h. 600 The value is 0.6. The formula of the culture medium is: 1% yeast extract, 2% tryptone, 20g / L glycerol, 10g / L glucose, and 10g / L lactose.

[0134] (2) Determination of carbon source and product in fermentation broth

[0135] The concentrations of 2′-fucosyllactose, glucose, and glycerol were determined by high performance liquid chromatography, specifically:

[0136] Thermo UltiMate 3000 high performance liquid chromatography and Dikma CarboPac H+6μm chromatographic column were used; the column temperature was set to 50°C, the differential refractive index detector temperature was set to 35°C; 5mM H2SO4 was used as the mobile phase (0.8mL / min). Fermentation broth treatment method: 1mL of the fermentation broth prepared in this comparative example was boiled for 10min to lyse the cells, the supernatant was collected by centrifugation (12 000g, 20min) and detected by high performance liquid chromatography. The results are shown as follows: Fig.12 As shown by Fig.12The results show that after 96 hours of fermentation, the final titer of 2′-fucosyllactose in YR02 in Example 3 was 7.45 g / L, which was 31.4% higher than the yield of recombinant bacteria 1 in Example 3, indicating that after knocking out the Pfk gene, the yield of 2′-fucosyllactose can be significantly increased under a mixed carbon source of glycerol and glucose.

[0137] Comparative Example 3 Construction of pLU-Lac12 recombinant plasmid

[0138] Using the pUU-Lac12 plasmid as a template, PCR amplification was performed using primers 6-F and 6-R to obtain 4UAS-P TEF -Lac12 fragment, the original pLU plasmid vector was cut with restriction endonucleases Nhe I and Hind III to obtain a linearized pLU plasmid vector, and then the 4UAS-P was transformed into the 4UAS-P using the homologous recombinase C115. TEF -Lac12 fragment was connected with the linearized pLU recombinant plasmid vector to obtain the pLU-Lac12 recombinant plasmid, and the obtained pLU-Lac12 recombinant plasmid was introduced into Escherichia coli XL-10 competent cells for storage and amplification.

[0139] Comparative Example 4: Construction method of recombinant Yarrowia lipolytica with high 2′-fucosyllactose production

[0140] The construction method of the recombinant Yarrowia lipolytica with high 2′-fucosyllactose production in Comparative Example 4 is basically the same as that of the recombinant bacteria 3 (YR-07) ​​in Example 3. The recombinant Yarrowia lipolytica in this comparative example is constructed on the basis of the recombinant bacteria 2 (YR-02). The difference is that the pLU-Lac12 recombinant plasmid constructed in Comparative Example 3 is used to replace the pLU-FGG recombinant plasmid in the construction of the recombinant bacteria 3 in Example 3, and the obtained recombinant bacteria is named YR03.

[0141] Comparative Example 5 Construction method of recombinant Yarrowia lipolytica with high production of 2′-fucosyllactose

[0142] The construction method of the recombinant Yarrowia lipolytica with high 2′-fucosyllactose production in Comparative Example 5 is basically the same as that of the recombinant bacteria 3 (YR-07) ​​in Example 3. The recombinant Yarrowia lipolytica of this comparative example is constructed on the basis of the recombinant bacteria 2 (YR-02), except that the pLU-FGG recombinant plasmid constructed in step b of the construction of the pLU-FGG recombinant plasmid in Example 2 (2) is used to replace the pLU-FGG recombinant plasmid in the construction of the recombinant bacteria 3 in Example 3, and the obtained recombinant bacteria is named YR04.

[0143] Comparative Example 6

[0144] The application of different recombinant Yarrowia lipolytica in the production of 2′-fucosyllactose is as follows:

[0145] (1) Production of 2′-fucosyllactose by shake flask fermentation

[0146] The strains YR02 constructed in Example 3, YR03 constructed in Comparative Example 4, YR04 constructed in Comparative Example 5, and YR07 constructed in Example 3 were inoculated into 250 mL shake flasks containing 30 mL of culture medium and fermented on a shaker at 30 ° C and 220 rpm for 96 h. The initial OD 600 The value is 0.6. The formula of the culture medium is: 1% yeast extract, 2% tryptone, 20g / L glycerol, 10g / L glucose, and 10g / L lactose.

[0147] (2) Determination of carbon source and product in fermentation broth

[0148] The concentration of 2′-fucosyllactose was determined by HPLC, specifically:

[0149] Thermo UltiMate 3000 high performance liquid chromatography and Dikma CarboPac H+6μm chromatographic column were used; the column temperature was set to 50°C, the differential refractive index detector temperature was set to 35°C; 5mM H2SO4 was used as the mobile phase (0.8mL / min). Fermentation broth treatment method: 1mL of the fermentation broth prepared in this comparative example was boiled for 10min to lyse the cells, the supernatant was collected by centrifugation (12 000g, 20min) and detected by high performance liquid chromatography. The results are shown as follows: Fig.13 As shown by Fig.13 The results showed that under the same conditions, compared with YR02 (2′-fucosyllactose production of 7.47 g / L), the yield of YR03 did not change significantly (2′-fucosyllactose production of 7.39 g / L), and the yield of YR04 increased slightly to 8.02 g / L. The 2′-fucosyllactose production of YR07 increased significantly to 8.71 g / L, an increase of 16.6%. Therefore, it was shown that the three key genes GDP-mannose-4,6-dehydratase (Gmd), GDP-L-fucose synthase (Gmer) and fucosyltransferase (FutC) in the 2′-fucosyllactose synthesis pathway were strengthened by the Yarrowia lipolytica enhanced promoter 4UAS-PTEF or 8UAS-PTEF, which could significantly increase the production of 2′-fucosyllactose.

[0150] The above is only a preferred embodiment of the present invention, and the present invention is not limited to the above embodiments. It is understood that other improvements and changes directly derived or associated by those skilled in the art without departing from the spirit and concept of the present invention should be considered to be included in the protection scope of the present invention.

Claims

1. A recombinant Yarrowia lipolytica with high 2'-fucosyllactose production, characterized in that: The recombinant Yarrowia lipolytica chromosome integrates and expresses the lactose transporter Lac12 gene, the enhanced GDP-mannose-4,6-dehydratase Gmd gene, the enhanced GDP-L-fucose synthase Gmer gene, and the enhanced SUMO-tagged fucosyltransferase SUMO-FutC gene, and knocks out the 6-phosphofructokinase Pfk gene on the chromosome.

2. The recombinant Yarrowia lipolytica according to claim 1, characterized in that The recombinant Yarrowia lipolytica uses Yarrowia lipolytica Po1f as a host.

3. The recombinant Yarrowia lipolytica according to claim 1, characterized in that The nucleotide sequence of the Lac12 gene is shown in SEQ ID NO.3; the nucleotide sequence of the Gmd gene is shown in SEQ ID NO.4; the nucleotide sequence of the Gmer gene is shown in SEQ ID NO.5; the nucleotide sequence of the SUMO-FutC gene and the Lac12 gene is shown in SEQ ID NO.6; the NCBI gene number of the 6-phosphofructokinase Pfk gene is YALI2_D00323g; the promoters of the Gmd gene, Gmer gene, and SUMO-FutC gene are the Yarrowia lipolytica promoter P TEF , the terminator is the Yarrowia lipolytica terminator T LIP .

4. The recombinant Yarrowia lipolytica according to claim 1, characterized in that The copy number of the lactose transporter Lac12 gene is 1, the copy number of the enhanced GDP-mannose-4,6-dehydratase Gmd gene is 2, the copy number of the enhanced GDP-L-fucose synthase Gmer gene is 2, and the copy number of the enhanced SUMO-tagged fucosyltransferase SUMO-FutC gene is 2; the enhancing element used to enhance the Gmd gene and the Gmer gene is 4UAS; the enhancing element used to enhance the SUMO-FutC gene is 4UAS and / or 8UAS.

5. The recombinant Yarrowia lipolytica according to claim 1, characterized in that The recombinant Yarrowia lipolytica uses the original pUU plasmid vector and / or the original pLU plasmid vector as an integrated expression vector; the sequence of the original pUU plasmid vector is shown in SEQ ID NO.1; The original pLU plasmid vector is shown as SEQ ID NO.

2.

6. A method for constructing the recombinant Yarrowia lipolytica according to any one of claims 1 to 5, characterized in that: The construction method comprises the following steps: (1) Insert the target gene Lac12 gene, Gmd gene, Gmer gene, and SUMO-FutC gene into the BamH I and Hind III sites of the original PUU plasmid vector, respectively, to obtain pUU-Lac12 plasmid, pUU-Gmd plasmid, pUU-Gmer plasmid, and pUU-FutC plasmid; (2) PCR amplification was performed using pUU-Lac12 plasmid, pUU-Gmd plasmid, and pUU-Gmer plasmid as templates to obtain P TEF -Lac12-T LIP Expression cassette, 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP expression cassette; pUU-FutC plasmid was digested with restriction endonuclease EcoR I to obtain linearized pUU-FutC plasmid, and then 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP Expression cassette, P TEF -Lac12-T LIP The expression cassette was ligated with the linearized pUU-FutC plasmid vector to obtain the pUU-FGGL recombinant plasmid; (3) PCR amplification was performed using the pUU-FutC plasmid as a template to obtain the SUMO-FutC fragment, and the original pLU plasmid vector was digested with restriction endonucleases BamHI and Hind III to obtain a linearized pLU plasmid vector. The SUMO-FutC fragment was then connected to the linearized pLU plasmid vector using the homologous recombinase C115 to obtain the pLU-FutC recombinant plasmid. Then, PCR amplification was performed using the pUU-Gmd plasmid and the pUU-Gmer plasmid as templates to obtain the 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP expression cassette; the pLU-FutC recombinant plasmid was digested with restriction endonuclease Sal I to obtain a linearized pLU-FutC recombinant plasmid vector, and then the 4UAS-P TEF -Gmd-T LIP Expression cassette, 4UAS-P TEF -Gmer-T LIP The expression cassette was connected to the linearized pLU-FutC recombinant plasmid vector to obtain the pLU-FGG recombinant plasmid; (4) using restriction endonuclease Not I to digest the pUU-FGGL recombinant plasmid to obtain a linearized pUU-FGGL recombinant plasmid, transforming it into competent cells of Yarrowia lipolytica Polf for homologous recombination, and then introducing the pYLXP-Cre plasmid to eliminate the Ura selection marker after screening and PCR identification, and then obtaining positive clones successfully introduced with the pYLXP-Cre plasmid after screening and PCR identification, and then continuously passaged to lose the pYLXP-Cre plasmid to obtain recombinant bacteria 1; (5) The recombinant plasmids pg7-Leu and pCg58-Ura3 were transformed into recombinant bacteria 1, and the pfk gene was knocked out by CRISPR-Cas9 technology. The colonies with successful knockout of the pfk gene were obtained by screening and colony PCR identification, and the recombinant plasmids pg7-Leu and pCg58-Ura3 were lost by subculture to obtain recombinant bacteria 2; (6) The pLU-FGG recombinant plasmid was recombined using restriction endonuclease Not I to obtain a linearized pLU-FGG recombinant plasmid, which was transformed into competent cells of the recombinant bacteria 2 for integration. After screening and PCR identification, a recombinant Yarrowia lipolytica strain with high 2'-fucosyllactose production that was correctly identified by PCR was obtained.

7. Use of the recombinant Yarrowia lipolytica according to claim 1 or the recombinant Yarrowia lipolytica constructed by the construction method according to claim 6 in producing 2'-fucosyllactose.

8. The use according to claim 7, characterized in that: After the recombinant Yarrowia lipolytica is activated, it is inoculated into a fermentation medium for fed-batch fermentation to obtain 2'-fucosyllactose.

9. The use according to claim 8, characterized in that: The fermentation medium is 2×YPG liquid medium, and the initial OD of the recombinant Yarrowia lipolytica in the fermentation medium is 600 The value is 0.5-1.0; the temperature of the fed-batch fermentation is 28-30°C, the rotation speed is 200-1200rpm, the dissolved oxygen content is 15-25%, the ventilation volume is 3v / v / min, and the pH is 6.0; the fed-batch fermentation is specifically as follows: when the fermentation is 12h, 10g / L lactose is added to the culture medium to prepare 2'-fucosyllactose, and when the initial glycerol in the culture medium is consumed, 3.5-4.5g / L / h glycerol, 1.5-2.0g / L / h glucose and 0.5-1.3g / L / h lactose are added by flow, and the total fermentation time is 132h.

10. The use according to claim 7, characterized in that: The titer of the 2'-fucosyllactose is 102.82 g / L, and the production efficiency is 0.86 g / L / h.

Citation Information

Cited By

  • The high yield is 2apos; engineering strain of fucosyllactose as well as construction method and application of engineering strain

    CN116622534A

  • Engineered strain for high-yield 2'-fucosyllactose and construction method and application thereof

    CN116622534B

  • Genetically engineered bacterium for producing 2 '-fucosyllactose based on mannitol as well as construction method and application of genetically engineered bacterium

    CN119570647A

  • Method for constructing bacterial mutant library and application thereof

    CN120505711A